bioAffinity Technologies

CyPath Lung’s noninvasive sputum-based triage value for high-risk patients with indeterminate pulmonary nodules drives physician ordering, because it can help decide who needs timely invasive follow-up and who can continue screening. If this holds, the company has a real commercial product rather than a research platform; if it breaks, the revenue base remains too small for the current cost structure.

Owning PPLS gives bioAffinity a controlled commercial laboratory channel for CyPath Lung, reducing dependence on third-party labs and letting the company refine operations, test delivery, and sales execution directly. If the owned lab channel works, adoption can convert into revenue more directly; if lab operations or compliance falter, the commercialization path is impaired.

Management’s decision to discontinue unprofitable pathology services should improve the business mix only if CyPath Lung volume absorbs the lab cost base and creates better long-term margin potential. This is the bridge from scientific promise to shareholder value: growth that does not improve losses will likely require more dilutive financing.

The 2026 longitudinal multicenter study can turn CyPath Lung’s early performance claims into the clinical evidence needed for broader adoption, reimbursement discussions, and a more defensible diagnostic position. If the study validates clinical utility, the company’s addressable market and credibility expand; if it disappoints, the product’s moat and commercial argument weaken sharply.

Equity financing must bridge the commercialization and clinical-study period without forcing repeated highly dilutive raises before CyPath Lung proves it can scale. Even if the product works, owners can lose if the company has to fund the ramp by issuing too much stock at weak prices.